SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and intense community debate as the token's massive price surge triggers accusations of market manipulation and pump-and-dump schemes, while supporters point to upcoming global music events and utility as catalysts for long-term growth. Investors remain sharply divided, with some actively trading the short squeezes and liquidations, while others issue urgent warnings about concentrated token ownership and the high risk of a potential collapse.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining momentum as investors position it as an under-the-radar micro-cap play within the competitive AI and Web3 infrastructure sector. The community is actively debating its long-term potential compared to established GPU-compute projects, with many highlighting its perceived growth trajectory and early-stage status as key catalysts for engagement.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus is trending as its community emphasizes long-term organic growth and viral culture over short-term hype during recent market volatility. Investors are actively discussing the token's resilience and its strategic partnerships within the Solana memecoin ecosystem as they build toward future milestones.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech is currently trending as investors weigh a major share buyback program and aggressive insider purchasing by the CEO against bearish technical signals and concerns over revenue guidance. The community is actively debating whether the stocks recent volatility presents a deep value opportunity or if ongoing macroeconomic and sector-specific risks will drive shares lower.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares (LABU) is actively trending as investors flock to the biotech sector amidst a mix of buyout activity, optimism surrounding AI-driven drug discovery, and a broader market rotation into small-cap and healthcare equities. The community remains deeply divided, with some traders highlighting the ETF's recent aggressive price appreciation as an indicator of a potential parabolic blow-off top, while others continue to bet on further gains driven by anticipated Federal Reserve interest rate policy changes.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares (LABD) is experiencing heavy retail activity as traders weigh ongoing geopolitical instability and sector-specific volatility against the broader market's bullish momentum. The community is actively debating the sustainability of the XBI index's recent price levels, with many traders strategically averaging down or scalping intraday moves while waiting for a anticipated technical reversal in biotech valuations.

Highstreet

Highstreet is experiencing intense community debate, with some traders optimistic about a potential short squeeze given the token's significant retracement from previous highs, while skeptics warn of volatility and erratic price action. Discussion is heavily focused on whale accumulation patterns and the potential for a rebound as participants speculate on whether the current entry point represents a discount or a continued downward trend.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as investors react to a significant Trump-led executive order that fast-tracks the review of psychedelic-based mental health treatments. While the community is actively debating the potential for an FDA fast-track for COMP360 and whether the regulatory tailwinds will drive a market re-rating, sentiment remains divided between those expecting a major sector-wide surge and skeptics urging caution regarding long-term clinical timelines and management execution.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco Corp is surging following the announcement of a massive strategic partnership with Brookfield and the U.S. government to invest billions into new nuclear reactor deployment to meet AI energy demands. The community is heavily focused on this shift toward nuclear as essential infrastructure for data centers, with many traders riding the momentum while debating whether the stock's parabolic move is overextended or just the beginning of a long-term supply bottleneck play.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant conversation as traders pivot between optimistic staking accumulation and aggressive short-term trading of volatile meme coins. The community remains focused on potential regulatory catalysts and ecosystem expansion, while debates continue over whether to treat the current price action as a structural bottom or a trap for retail investors.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Galapagos NV (NASDAQ:GLPG) Expands By 20.4%

Galapagos NV (NASDAQ:GLPG - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,096,114 shares, an increase of 20.4% from the March 15th total of 910,692 shares. Currently, 1.7% of the company's...

Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average - Time to Sell?

Galapagos (NASDAQ:GLPG) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell...

Galapagos NV (NASDAQ:GLPG) Given Average Recommendation of "Hold" by Analysts

Galapagos NV (NASDAQ:GLPG - Get Free Report) has been assigned an average recommendation of "Hold" from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One...

Galapagos Partners With Gilead on Gamgertamig, Unlocks $500M Cash and Eyes 2027 Registrational Trials

Galapagos (NASDAQ:GLPG) said it has entered into a binding collaboration agreement with Gilead focused on Gamgertamig, a BCMA x CD3 T-cell engager being developed for autoimmune diseases. Chief Executive Officer Henry Gosebruch said the deal follows "advanced discussions" disclosed the prior week an...

Galapagos (NASDAQ:GLPG) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Galapagos from a "hold" rating to a "buy" rating in a research note on Saturday...

Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal

GILD expands into autoimmune therapies with an acquisition deal with Ouro Medicines, adding OM336 and advancing its push into next-gen immunology platforms.

Galapagos (NASDAQ:GLPG) Sees Large Volume Increase - Still a Buy?

Galapagos (NASDAQ:GLPG) Sees Large Volume Increase - Should You Buy...

Galapagos Q4 Earnings Call Highlights

Galapagos (NASDAQ:GLPG) executives used the company's year-end 2025 financial results call to outline a strategic reset centered on business development, following a decision to wind down its cell...

Galapagos (NASDAQ:GLPG) Shares Gap Up Following Earnings Beat

Galapagos (NASDAQ:GLPG) Shares Gap Up Following Better-Than-Expected Earnings...

<ul class="summary-bullets"><li>The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company said.&nbsp;</li><li>It will also result in the shut down of sites in the Netherlands, Switzerland, U.S. and China.</li><li>Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.</li></ul> Galapagos NV (GLPG) on Monday announced that its Board of Directors has decided to initiate the wind-down of the company’s cell therapy activities, sending shares up 6% in Monday’s after hours trading.The company had announced its intent to wind down the activities after a strategic review and sale process in October but had held on acting on it until it completed communicating with work councils in the Belgium and Netherlands. The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3213177/0/en/Galapagos-Announces-Board-Decision-to-Initiate-Wind-Down-of-Cell-Therapy-Activities.html">said</a>.It will also result in the shut down of sites in the Netherlands, Switzerland, the U.S. and China. The U.S. facilities to be shut down include one in Princeton and another in Pittsburgh, the company said. More details about the wind down, including details pertaining to its timeline and costs, will be provided with the company’s full year earnings in February, it added.Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.<h2 class="st-heading-2">Future After Wind Down</h2>On Monday, Galapagos said that the wind-down of the cell therapy activities will position it for longer-term growth. The company will continue to manage its non-cell therapy programs and evaluate all strategic alternatives for GLPG3667, an investigational, oral, selective inhibitor of tyrosine kinase 2, to accelerate its development in dermatomyositis and potentially other severe auto-immune indications, the company said.The company will also consider resuming the partnering process for the drug, it said. Galapagos also added that it will continue to maintain its presence at its headquarters in Belgium as well as its hubs in Chicago and San Francisco.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment about GLPG stayed in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> has gained 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-us-sales-rise-8-percent-in-q4/cmxMCZPR4Ri">US Heeds Trump To Buy A Toyota: Japanese Automaker’s US Sales Rise 8% In Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A logo of Galapagos, a European pharmaceutical research company, is pictured outside its facility on June 9, 2020 in Leiden, Netherlands. (Photo by Yuriko Nakao/Getty Images) 

Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction 

The company had announced its intent to wind down the activities after a strategic review and sale process in October.

Equity

The company had announced its intent to wind down the activities after a strategic review and sale process in October.


Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

GLPG
Galapagos

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GLPG News

GLPGGalapagos